Ekf Diagnostics Holdings Plc · LSE:EKF
Ekf Diagnostics — Renalytix AI — IPO Roadshow (October 2018)
23 slides from Ekf Diagnostics's IPO roadshow presentation, October 2018
Slide 1: Artificial Intelligence for Kidney Disease
ARTIFICIAL INTELLIGENCE FOR KIDNEY DISEASE RENALNTIXAI CONFIDENTIAL
Slide 2: Disclaimer
Disclaimer This presentation document has been prepared by Renalytix AI plc ("RenalytixAI”) for information purposes only in relation to the proposed restricted offer of ordinary shares to certain qualifying shareholders of EKF Diagnostics Holdings plc in the capital of RenalytixAI (the “Ordinary Sh
Slide 3: Presenter recent experience
Presenter recent experience James McCullough Julian Baines Chief Executive Officer Chairman RenalytixAI EKF Diagnostics Co-Founder, CEO CEO Artificial Intelligence Kidney Diagnostics Global medical device manufacturer Exclusive partnership Icahn School of Medicine at Mount Sinai Completed 8 acquisit
Slide 4: Presenter recent experience (continued)
Presenter recent experience (continued) Barbara Murphy, MD Erik Lium, PhD Proposed Non-Exec Director Proposed Non-Exec Director Mount Sinai Health System Mount Sinai Innovation Partners Murray M. Rosenberg Professor of Medicine and Executive Vice President Chair of the Samuel Bronfman Department of
Slide 5: Overview of RenalytixAI
Overview of RenalytixAI ▪ Developing artificial intelligence (“AI”) enabled clinical decision support tools for improved kidney disease risk assessment and clinical care ▪ Addressing one of the largest and costliest chronic medical conditions globally, estimated to affect over 850 million people wor
Slide 6: Quote from Dr. Steven Coca on kidney disease and AI
“The state of affairs in kidney disease is so poor that a quantum leap is available to us with artificial intelligence. We can transform how we identify, monitor and treat one of the largest and costliest diseases in history.” Dr. Steven Coca, Co-Founder, RenalytixAI Associate Professor, Medicine, N
Slide 7: Our approach
Our approach ▪ Building one of the deepest pools of EHR-linked kidney disease data for AI application development ▪ Decision support solutions for at-risk diabetic and African ancestry populations served by major medical centers ▪ Cornerstone collaboration with the Icahn School of Medicine at Mount
Slide 8: Investment case
Investment case Very large addressable market Expected first Cornerstone deal in place Expected to be first to submit Mount Sinai collaboration provides Kidney disease is one of largest AI-enabled kidney disease products access to 3M patient records and unmet medical needs today to FDA large at-risk
Slide 9: A public epidemic: current standard not working
A public epidemic: current standard not working Most patients show no signs until Annual cost of dialysis kidney function degraded by 80% $88k Current standard per patient Too late to prevent Cannot assess all patients Late diagnosis No precision biomarkers Major cost No complex data integration Poo
Slide 10: KidneyIntelX - Launch product
KidneyIntelX™ - Launch product ▪ Expected to be first AI-driven solution in kidney disease submitted for FDA review ▪ Low barriers to adoption with custom report capability to primary care, diabetology, endocrinology, nephrology Risk Scoring Blood Biomarkers Massive Machine Learning Engine Multi-ins
Slide 11: Revenue strategy
Revenue strategy The Company’s revenue is expected to be derived from different sources including: (1) Third-party and government reimbursement models for developed products, such as KidneyIntelX™ (2) Subscription models (e.g. quarterly) for ongoing monitoring of kidney risk (3) Program development
Slide 12: Major data access and product development partnership
Major data access and product development partnership License and collaboration agreement May 2018: ▪ ISMMS expected to purchase up to $6.0M KidneyIntelX™ tests beginning 2019* ▪ Large diabetes and African ancestry populations ▪ 3,000,000 electronic health records ▪ 43,000 patient unique biobank Mou
Slide 13: Partnering with a software development leader to build technology platform
Partnering with a software development leader to build technology platform 28+ Publically listed in $470m FY’18 28+ years 5,500+ product India (BSE, NSE) revenue in business releases since 2012 800+ customers: 14 top technology companies Source: Persistent marketing presentation 13
Slide 14: KidneyIntelX - Analysis of expected cost savings
KidneyIntelX™ - Analysis of expected cost savings 1 2 3 Slowed progression through Delayed or prevented Fewer emergency room Chronic Kidney Disease dialysis and transplants events and dialysis crashes (CKD) stages Risk assessment/awareness to slow or Earlier intervention delays/prevents Timely warni
Slide 15: Demonstrated short & long term behavior, cost, mortality impact
Demonstrated short & long term behavior, cost, mortality impact Utility Description Peer review Therapeutics Drug interventions (ACEi/ARB, aggressive BP control) to reduce risk for ACEi/ARB (multiple) decline in kidney function and CVD in patients at risk/with CKD Aggressive BP Control (AASK, SPRINT
Slide 16: Expected milestones to launch and growth
Expected milestones to launch and growth 2018 2019 2020-2021 Collaboration with ISMMS KidneyIntelX™ multi-center utility begins FDA clearances KidneyIntelX™ CLIA validation KidneyIntelX™ FDA full submission CMS reimbursement KidneyIntelX™ FDA pre-sub FractalDx CLIA validation Multi
Slide 17: Indicative Use of Proceeds (£m)
Indicative Use of Proceeds (£m) £21m Raise £25m Raise Product Development / AI 4.7 Product Development / AI 7.1 Corporate 4.2 Corporate 4.4 Licenses & Royalties 9.3 Licenses & Royalties 9.3 Capex 0.4 Capex 0.7 Working Capital 1.5 Working Capital 1.7 Reserve 0.9 Reserve 1.8 21.0 25.0 Notes 1. Initial
Slide 18: IPO Summary and Timetable for Restricted Offer
IPO Summary and Timetable for Restricted Offer Fundraising comprises Placing, Subscription (US Reg D Placement) and Restricted Offer (to EKF shareholders only) Total size: £21 – 25m (approx.) Value: £42.9m (approx.) pre-new money Fundraising shares: 32.9% – 36.8% of enlarged share capital Distributi
Slide 19: Glossary
Glossary “ACEi” Angiotensin converting enzyme inhibitor “ESRD” End stage renal disease “APOL1” Apolipoprotein L-1 “FDA” US Food and Drug Administration “ARB” Angiotensin receptor blockers “GM” Gross margin “AUC” Area under the plasma drug concentration-time curve “HD” Home hemodialysis “BP” Blood pr
Slide 20: Supplemental
SUPPLEMENTAL RENAL\TIXAL sonra
Slide 21: Board and Management
Board and Management James McCullough, CEO, Executive Director Julian Baines, Executive Chairman Partner, Renwick Capital; former CEO, Exosome Group CEO, EKF Diagnostics Holdings plc; Diagnostics; founding advisor, PAIGE.AI former CEO & Managing Director BBI Holdings plc Christopher Mills, Non-Execu
Slide 22: Advisory Board
Advisory Board Barbara Murphy, MD. Chair of Advisory Board Girish Nadkarni, MD, co-Founder Murray M. Rosenberg Professor of Medicine; Assistant Professor of Medicine, Division of Chair of the Department of Medicine for the Mount Nephrology; Clinical Director of the Charles Sinai Health System; Dean
Slide 23: Contact
Contact James McCullough Chief Executive Officer RenalytixAI 1460 Broadway New York, NY 10036, USA +1 646 397 3970 www.renalytixai.com jmccullough@renalytixai.com 23